INSTITUTO-COORDENADAS
13.10.2020 12:46:08 CEST | Business Wire | Press release
Barcelona’s efforts to become a safe destination for tourists have meant that, of all of Europe’s main tourism destinations, the city and its surrounding areas have been ranked as one of most committed to health safety matters. Monitoring and advice, alongside the involvement of the tourism sector’s main actors, have provided Barcelona with international acknowledgment that will benefit the sector’s recovery. Those are the main conclusions of an ongoing study by Institute Coordenadas into the impact of Covid-19 on the tourism industry.
One of the key indicators that place Barcelona at the forefront for safe spaces internationally is the backing for the city from the World Travel and Tourism Council (WTTC), which has launched a global quality stamp for tourist destinations that provided the strongest guarantees that their public spaces are Covid-secure. Barcelona is a member of the elite group of major European cities that safely welcome a high number of tourists. As such, the city is striving to provide the safest conditions for visitors, around 28 million of whom come to the Catalan capital every year, joining its population of just over 1.6 million. Seville was also acknowledged by the WTTC, along with other destinations in Portugal, Saudi Arabia and Cancun, Mexico.
Barcelona’s seventh position (and the title of top-ranked Spanish city) in the Saffron City Brand Barometer 2020 of the cities with the strongest tourism brands is also a key factor. Similarly, the Global Safe Site certification from Bureau Veritas highlights strict compliance with hygiene and safety measures in Barcelona, which was also the first Spanish city to be awarded the distinction. Key tourist infrastructure such as Park Güell, the city’s zoo and the Tibidabo amusement park have all been awarded the Safe Tourism Certified distinction by the Institute for Spanish Tourism Quality (ICTE), which marks the implementation of a specific Covid-19 risk prevention system. Furthermore, Barcelona has been Biosphere-certified since 2011 as an urban destination committed to sustainability.
The website promoted by Barcelona City Council as part of the Barcelona Safe City/Safe Visit initiative is a key element in the process of getting the city moving again post-Covid. The portal can be used by companies and professionals to check the information related to their respective fields and for obtaining a personalised report featuring all the necessary elements to ensure protocols adapt to maximum safety requirements.
The involvement of actors from different municipal levels has been one of the factors that has allowed Barcelona to compete to become a safer city in terms of health. The Safe City initiative included an interdisciplinary working group with members from the Catalan Directorate of Tourism, the Public Health Agency of Catalonia, the Municipal Civil Defence Service, the Guàrdia Urbana municipal police force, BCNecologia/Barcelona Urban Ecology Agency, the city’s Department of Commerce, its Culture Institute and the Barcelona Sports Institute, municipal company B:SM, trade fair organisation Fira de Barcelona, the Turisme de Barcelona Consortium and ISGlobal.
Another aspect that will improve safety features for tourists in Barcelona is the introduction of the app currently being put together by the Turisme de Barcelona Consortium and Barcelona City Council. The app will allow users to check on health recommendations and the situation at visitor locations, so as to avoid crowds and queueing. The app’s initial launch phase will feature opening times and entry points for the most popular tourist destinations, along with guidance for health and mobility. Plans for the second phase include real-time information and the option of booking ahead to ensure safer management of tourist activities. The app is being developed by Eurecat Technology Centre in collaboration with the Mobile World Capital Barcelona Foundation and Barcelona Tech City.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
